v3.26.1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Research and development revenue $ 3,524 $ 5,065 $ 7,515 $ 11,772
Cost of revenue (2,411) (2,775) (4,375) (6,314)
Gross profit 1,113 2,290 3,140 5,458
Operating costs and expenses:        
Research and development 1,696 1,457 3,258 2,770
General and administrative 3,088 2,616 5,316 5,061
Selling and marketing 653 340 861 646
Total operating costs and expenses 5,437 4,413 9,435 8,477
Operating loss (4,324) (2,123) (6,295) (3,019)
Other income (expense):        
Net interest expense (378) (397) (815) (417)
Financing related costs (5) (4) (12) (585)
Change in fair value of warrant liability 711 (5,449) (291) (1,196)
Change in fair value of notes payable 220
Foreign exchange transaction loss, net (10) (14) (15) (22)
Total other income (expense), net 318 (5,864) (1,133) (2,000)
Loss before income taxes (4,006) (7,987) (7,428) (5,019)
Income tax provision (170) 19 (160) (52)
Net loss $ (4,176) $ (7,968) $ (7,588) $ (5,071)
Net loss per share of common stock        
Basic (in Dollars per share) $ (0.13) $ (0.31) $ (0.24) $ (0.21)
Diluted (in Dollars per share) $ (0.13) $ (0.31) $ (0.24) $ (0.21)
Weighted average common shares outstanding        
Basic (in Shares) 32,080,874 25,421,560 31,922,459 24,409,550
Diluted (in Shares) 32,080,874 25,421,560 31,922,459 24,409,550
Other comprehensive income (loss):        
Foreign currency translation adjustments $ (1) $ 32 $ (11) $ 49
Total comprehensive loss $ (4,177) $ (7,936) $ (7,599) $ (5,022)